ArticleFrontiers in immunology2026
A full-thickness spatial transcriptomics atlas of medically refractory ulcerative colitis identifies niche signatures associated with biologic non-response.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) is a chronic mucosal immune disorder in which 30-50% of patients fail biologic therapy, yet the full-thickness immune architecture of medically refractory disease and reliable tissue-level markers of treatment response remain undefined. Methods: Using 10x Visium HD spatial transcriptomics (16-µm bins; 615,274 bins), we generated a full-thickness spatial atlas of surgically resected colon from patients with medically refractory UC (n=3) and controls (n=3), integrating niche-stratified differential expression, spatial cell-cell communication, SCENIC regulon inference and single-sample GSEA with immunofluorescence and DSS-colitis flow cytometry. Results: We resolved 18 spatial immune-stromal niches across five tissue modules. At the mucosal frontline, epithelial barrier collapse was accompanied by a 20-fold expansion of ulcer-bed stroma (p=0.030) that co-localised with an Acute Neutrophil Niche and was associated with neutrophil recruitment via CXCL12-CXCR4 signalling, forming a spatially integrated ulcerogenic unit. In the submucosa, a humoral immune programme was associated with tertiary lymphoid structures (TLS) and plasma-cell survival-related signalling (MIF-CD74 and LTB-CD40). This niche architecture was immunologically informative: an Acute Neutrophil Niche signature was enriched in biologic non-responders across six adult cohorts (AUC 0.67-0.99) and in non-remission patients of the paediatric PROTECT cohort, and a five-niche model showed discriminative performance in adult cohorts across independent datasets and drug classes (anti-TNF and anti-integrin; cross-cohort AUC 0.68-0.97), although this performance did not transfer to the paediatric cohort (AUC ≈ 0.51-0.62). Expansion of TNFAIP2+ TLS-resident B cells was confirmed at the protein level in a DSS colitis mouse model by immunofluorescence and flow cytometry (p=0.0079). Conclusion: Together, this full-thickness atlas defines the spatial immune ecosystem of refractory UC - neutrophil niches, TLS and plasma-cell survival programmes - and yields cellular-niche signatures reproducibly associated with treatment outcome across drug classes, providing an immunologically grounded framework that may inform biologic selection, pending prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.